


CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/23-24/BSE -152

Date 14/02/2024

To

Department of Corporate Affairs
BSE Limited
P.J. Towers, Dalal Street
Mumbai -400001

Ref: Script code – 540694

Sub: Outcome of Board Meeting held on 14.02.2024 and Submission of Unaudited Financial Results for the quarter and nine months ended on 31st December, 2023.

Dear Sir/Madam,

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on Wednesday, 14th February, 2024 has considered and approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine month ended on December-31, 2023 along with the Limited Review Report thereon issued by M/s Singh Bhupinder & Associates, Statutory Auditors of the Company.


The Board meeting was commenced at 05:00 P.M. and concluded at 06:30 P.M.

This is for your information. Kindly take the same on your record.

Thanking you

Yours' faithfully

For ANG Lifesciences India Limited



Rajesh Gupta
Managing Director



INDEPENDENT AUDITOR'S REVIEW REPORT ON THE CONSOLIDATED UNAUDITED FINANCIAL RESULT OF THE COMPANY FOR THE QUARTER ENDED 31ST DECEMBER, 2023 AND YEAR TO DATE FROM 01ST APRIL, 2023 TO 31ST DECEMBER, 2023 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of ANG Lifesciences India Limited ("Holding Company") and its Subsidiary (the Holding and its subsidiaries together referred to as "the Group") for the quarter ended on 31st December, 2023 and year to date from 01st April, 2023 to 31st December, 2023 ("the statement") attached herewith being submitted by the Holding Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations")
2. This statement which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.
5. The Statement includes the result of the following entities:-

Mansa Print & Publishers Limited

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement in respect of matters stated is not modified with respect to our reliance on the work done and the financial results certified by the Management.

Place: Amritsar
Date: 14.02.2024

For Singh Bhupinder & Associates
Chartered Accountants



(Bhupinder Singh)

Prop.

FRN. 035417N

M. No. 513899

UDIN: 24513899BKADWC6130

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of consolidated unaudited results for the quarter and nine months ended 31 Dec 2023

(₹ in lakhs except per share data)

Particulars	Quarter ended 31 December 2023	Quarter ended 30 September 2023	Quarter ended 31 December 2022	Nine months ended 31 December 2023	Nine months ended 31 December 2022	Year ended 31 March 2023
	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)
I Revenue from operations	1,854.55	3,326.19	4,692.63	10,826.98	18,045.42	21,989.11
II Other income	(2.93)	22.34	23.85	51.06	49.08	972.35
III Total revenue (I+II)	1,851.62	3,348.53	4,716.48	10,878.04	18,094.50	22,961.46
IV Expenses						
Cost of materials consumed	1,357.83	2,201.40	3,281.33	6,973.11	11,736.94	15,608.02
Changes in inventories of finished goods and work-in-progress	(200.38)	(49.40)	(275.81)	31.89	(348.88)	(549.05)
Employee benefits expense	448.90	494.73	535.96	1,520.12	1,812.44	2,397.07
Finance costs	251.41	228.99	346.80	711.81	1,022.47	1,187.87
Depreciation and amortisation expenses	191.42	222.26	212.72	632.48	632.71	935.35
Other expenses	439.25	513.70	875.55	1,672.38	2,403.44	3,119.70
Total expenses (IV)	2,488.43	3,611.61	4,976.55	11,541.79	17,259.12	22,698.96
V Profit before exceptional items and tax (III-IV)	(636.81)	(263.09)	(260.07)	(663.74)	835.38	262.50
VI Exceptional items						
VII Profit before tax (V-VI)	(636.81)	(263.09)	(260.07)	(663.74)	835.38	262.50
Tax expense						
(1) Current tax	(47.14)	-34.61	(62.64)	0.13	325.73	210.87
(2) Deferred tax	3.44	3.26	(19.87)	-14.24	74.98	77.85
VIII Total tax expense (1+2)	(43.70)	-31.35	(82.51)	(14.11)	400.71	288.72
IX Profit for the period (VII-VIII)	(593.11)	-231.73	(177.56)	(649.63)	434.67	(26.22)
X Other comprehensive income:						
Items that will not be reclassified to profit or (loss)	-3.00	5.31	0.20	20.26	115.01	97.39
Income tax relating to items that will not be reclassified to profit or loss	(0.75)	(1.34)	(0.05)	(5.10)	(28.94)	(24.51)
XI Total comprehensive income (IX+X)	(590.87)	-227.76	(177.41)	(634.47)	520.74	46.66
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83
XIII Other equity						7,315.94
XIV Earnings per equity share (of ₹ 10/- each)						
- Basic and Diluted	(4.52)	-1.74	(1.36)	(4.86)	3.99	0.36

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

As per Ind-AS 108, Operating Segments have been defined and presented based on the regular review by the Company's Chief Operating Decision Maker to assess the performance of each segment and to make decision about allocation of resources. The accounting principles used in the preparation of the consolidated unaudited financial results are consistently applied to record revenue and expenditure in individual segments. Accordingly, the consolidated unaudited segment wise revenue, results, assets, and liabilities is as follows :

S.No.	Particulars	Quarter ended						Nine months ended		Year ended
		31 December	30 September	31 December	31 December	31 December	31 March	31 December	31 March	
		2023	2023	2022	2023	2022	2023	2023		
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		
1	Segment revenue									
	a) Pharmaceuticals	1,710.42	2,957.68	4,517.10	9,728.89	17,512.19	20,700.55			
	b) Printing and packagings	206.15	456.79	337.69	1,342.33	1,696.07	2,420.51			
	Total	1,916.57	3,414.47	4,854.79	11,071.22	19,208.26	23,121.06			
	Less: Inter segment revenue	62.01	88.28	162.16	244.23	1,162.84	1,131.95			
	Revenue from operations	1,854.56	3,326.19	4,692.63	10,826.99	18,045.42	21,989.11			
2	Segment results (profit before tax and finance cost from each segment)									
	a) Pharmaceuticals	(382.26)	(31.66)	46.48	(6.24)	1,744.71	1,239.35			
	b) Printing and packagings	(8.47)	10.79	40.25	66.00	113.14	226.25			
	Total	(390.74)	(20.87)	86.73	59.76	1,857.85	1,465.60			
	Less: Finance costs	246.07	242.22	346.80	723.51	1,022.47	1,203.10			
	Profit before tax	(636.81)	(263.09)	(260.07)	(663.74)	835.38	262.50			
	Particulars			As at	As at	As at	As at			
				31 December	30 September	31 December	31 March 2023			
				2023	2023	2022	(Audited)			
3	Segment Assets									
	a) Pharmaceuticals			22,360.84	23,344.09	25,763.82	24,448.18			
	b) Printing and packagings			3,475.74	3,589.59	2,496.30	3,522.11			
	Total Segment assets			25,836.58	26,933.67	28,260.12	27,970.29			
4	Segment liabilities									
	a) Pharmaceuticals			15,264.85	15,824.86	16,698.89	16,697.33			
	b) Printing and packagings			2,928.09	2,531.15	2,463.57	2,651.71			
	Total Segment liabilities			18,192.94	18,356.01	19,162.46	19,349.04			





INDEPENDENT AUDITOR'S REVIEW REPORT ON THE STANDALONE UNAUDITED FINANCIAL RESULT OF THE COMPANY FOR THE QUARTER ENDED 31ST DECEMBER, 2023 AND YEAR TO DATE FROM 01ST APRIL, 2023 TO 31ST DECEMBER, 2023 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of ANG Lifesciences India Limited ("the Company") for the quarter ended on 31st December, 2023 and year to date from 01st April, 2023 to 31st December, 2023 ("the statement") attached herewith being submitted by the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations")
2. This statement which is the responsibility of the Holding Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Amritsar
Date: 14.02.2024

For Singh Bhupinder & Associates
Chartered Accountants



(Bhupinder Singh)

Prop.

FRN. 035417N

M. No. 513899

UDIN: 24513899BKADWD5608

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of standalone unaudited results for the quarter and nine months ended 31 December 2023

(₹ in lakhs except per share data)

Particulars	Quarter ended 31 December 2023	Quarter ended 30 September 2023	Quarter ended 31 December 2022	Nine months ended 31 December 2023	Nine months ended 31 December 2022	Year ended 31 March 2023
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I Revenue from operations	1,710.41	2,957.68	4,517.10	9,728.89	17,512.19	20,700.55
II Other income	(9.14)	33.48	32.11	58.66	64.62	984.24
III Total revenue (I+II)	1,701.27	2,991.16	4,549.21	9,787.55	17,576.81	21,684.79
IV Expenses						
Cost of materials consumed	1,350.05	1,988.62	3,261.65	6,364.71	11,815.06	15,112.43
Changes in inventories of finished goods and work-in-progress	(221.06)	(20.02)	(217.95)	94.91	(341.38)	(422.17)
Employee benefits expense	353.08	397.09	442.80	1,223.88	1,547.06	2,027.43
Finance costs	199.49	195.92	283.58	589.19	920.99	1,032.43
Depreciation and amortisation expenses	201.81	197.06	191.79	592.50	570.00	851.63
Other expenses	399.57	460.05	816.78	1,517.79	2,225.37	2,876.12
Total expenses (IV)	2,282.94	3,218.73	4,778.65	10,382.98	16,737.10	21,477.87
V Profit before exceptional items and tax (III-IV)	(581.67)	(227.57)	(229.44)	(595.43)	839.71	206.92
VI Exceptional items						
VII Profit before tax (V-VI)	(581.67)	(227.57)	(229.44)	(595.43)	839.71	206.92
Tax expense						
(1) Current tax	(47.14)	(34.61)	(62.64)	0.13	325.73	210.87
(2) Deferred tax	(75.39)	12.05	(7.23)	(91.10)	77.17	62.27
VIII Total tax expense (1+2)	(122.53)	(22.56)	(69.87)	(90.97)	402.90	273.14
IX Profit for the period (VII-VIII)	(459.14)	(205.01)	(159.57)	(504.46)	436.81	(66.22)
X Other comprehensive income:						
Items that will not be reclassified to profit or (loss)	1.60	6.97	(0.24)	19.38	113.53	95.72
Income tax relating to items that will not be reclassified to profit or loss	(0.41)	(1.75)	0.06	(4.88)	(28.57)	(24.09)
XI Total comprehensive income (IX+X)	(457.95)	(199.80)	(159.75)	(489.96)	521.77	5.41
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83
XIII Other equity						7,247.69
XIV Earnings per equity share (of ₹ 10/- each)						
- Basic and Diluted	(3.51)	(1.53)	(1.22)	(3.75)	4.00	0.04

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Notes:

1. ANG Lifesciences India Limited is a public listed company incorporated in India and is in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, P/S, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syrups and Suspension, Lotions etc. ANG's products portfolio comprises of major therapeutic categories such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin, Beta Lactamase Inhibitor etc.
2. The above audited standalone and consolidated financial results for the quarter and nine months ended 31 December 2023 have been reviewed by the Audit Committee and approved by the Company's Board of Directors in their respective meetings held on 14 February 2024. The Statutory Auditors of the Company have expressed unmodified opinion on these results.
3. The above results of ANG Life Sciences India Limited ('the Company' or 'the Holding Company') and its subsidiary (the Holding and the subsidiary together referred to as 'the Group') have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and as per the presentation requirements of SEBI Circular CIR/CFD/FAC/62/2016 dated 05 July 2016 and other accounting principles generally accepted in India.
4. These financial results are available on the website of the Company at www.anglifesciences.com and are also available on the website of Bombay Stock Exchange at www.bseindia.com.
5. Previous period figures have been re-grouped/reclassified wherever necessary, to conform to current period's classification.

For and on behalf of the Board of Directors of
ANG Lifesciences India Limited

(Managing Director)

Place: Amritsar
Date: 14 February 2024